Illicit drug use in the pain patient population decreases with continued drug testing

Pain Physician

Volumn 14, Issue 2, 2011, Pages 189-193

  Pesce, Amadeo ^a   West, Cameron ^a   Rosenthal, Murray ^a   Mikel, Charles ^a   West, Robert ^a   Crews, Bridgit ^a   Almazan, Perla ^a   Latyshev, Sergey ^a   Horn, Paul S ^b  

^a Millenium Research Institute   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Decrease drug use; Illicit drugs; LC MS MS; Pain patients; UDT; Urine drug testing

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CANNABIS; COCAINE; DIAMORPHINE; DRUG METABOLITE; METHAMPHETAMINE; MORPHINE 6 ACETATE; PHENCYCLIDINE;

ARTICLE; CHRONIC PAIN; COHORT ANALYSIS; CONSULTATION; CORRELATION ANALYSIS; DRUG ABUSE; DRUG DEPENDENCE; DRUG USE; HUMAN; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; UNITED STATES; URINALYSIS; URINE DRUG TESTING;

ANALGESICS, OPIOID; CHROMATOGRAPHY, LIQUID; CHRONIC DISEASE; HUMANS; PAIN; RETROSPECTIVE STUDIES; STREET DRUGS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; TANDEM MASS SPECTROMETRY;

EID: 79952833337     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. National Prescription Drug Threat Assessment 2009. NDIC. 2009. Document ID: 2009-L0487-001. www.usdoj.gov/ndic/pubs33/33775/index.htm. Date Accessed 10/21/10.
2. Fisher F. Evaluating the risks of unwarranted prosecution part 1: The criminalization of pain management. Journal of American Physicians and Surgeons 2004; 9:114-117.
3. Manchikanti L, Singh A. Therapeutic opioids: A ten year perspective on the complexities and complications of the escalating use, abuse, and non-medical use of opioids and other psychotherapeutics. Pain Physician 2008; 11: S63-S88.
4. Reisfield GM, Salazar E, Bertholf RL. Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci 2007; 37:301-314.
5. Nafziger AN, Bertino JS. Utility and application of urine drug testing. Clin J Pain 2009; 25:73-79.
6. Katz NP, Sherburne S, Beach M, Rose RJ, Vielguth J, Bradley J, Fanciullo GJ. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg 2003; 97:1097-1102.
7. Michna E, Jamison RN, Pham LD, Ross EL, Janfaza D, Nedeljkovic SS, Narang S, Palombi D, Wasan AD. Urine toxicology screening among chronic pain patients on opioid therapy: Frequency and predictability of abnormal findings. Clin J Pain 2007; 23:173-179.
8. Trescot AM, Boswell MV, Atluri SL, Hansen HC, Deer TR, Abdi S, Jasper JF, Singh V, Jordan AE, Johnson BW, Cicala RS, Dunbar EE, Helm S 2nd, Varley KG, Suchdev PK, Swicegood JR, Calodney AK, Ogoke BA, Minore WS, Manchikanti L. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006; 9:1-39.
9. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: A rational approach to the treatment of chronic pain. Pain Med 2005; 6:107-112.
10. Donike M. The detection of doping by means of chromatographic methods. Drug Test Anal 2010 Dec 29.
11. Manchikanti L, Atluri S, Trescot AM, Giordano J. Monitoring opioid adherence in chronic pain patients: Tools, techniques and utility. Pain Physician 2008; 11:S155-S180.
12. Manchikanti L, Malla Y, Wargo BW, Cash KA, Pampati V, Damron KS, McManus CD, Brandon DE. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: A prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS). Pain Physician 2010; 13:E1-E22.
13. Pesce A, West C, West R, Crews B, Mikel C, Almazan P, Rosenthal M, Latyshev S. An evaluation of the diagnostic accuracy of liquid chromatography-tandem mass spectrometry versus immunoassay drug testing in pain patients. Pain Physician 2010; 13:273-281.
14. Pesce A, West C, Rosenthal M, West R, Crews B, Mikel C, Almazan P, Latyshev S, Horn PS. Marijuana correlates with use of other illicit drugs in a pain patient population. Pain Physician 2010;13:283-287.
15. Pesce A, Rosenthal M, West R, West C, Crews B, Mikel C, Almazan P, Latyshev S. An evaluation of the diagnostic accuracy of liquid chromatography-tandem mass spectrometry versus immunoassay drug testing in pain patients. Pain Physician 2010; 13:273-281.
16. Gilbert JW, Wheeler GR, Mick GE, Storey BB, Herder SL, Richardson GB, Watts E, Gyarteng-Dakwa K, Marino BS, Kenney CM, Siddiqi M, Broughton PG. Urine drug testing in the treatment of chronic noncancer pain in a Kentucky private neuroscience practice: The potential effect of Medicare benefit changes in Kentucky. Pain Physician 2010; 13:187-194.
17. Gilbert JW, Wheeler GR, Mick GE, Storey BB, Herder SL, Richardson GB, Watts E, Gyarteng-Dakwa K, Marino BS, Kenney CM, Siddiqi M, Broughton PG. Importance of urine drug testing in the treatment of chronic noncancer pain: Implications of recent medicare policy changes in Kentucky. Pain Physician 2010; 13:167-186.
18. Benyamin RM, Datta S, Falco FJE. A perfect storm in interventional pain management: Regulated, but unbalanced. Pain Physician 2010; 13:109-116.
19. Manchikanti L, Singh V, Boswell MV. Interventional pain management at crossroads: The perfect storm brewing for a new decade of challenges. Pain Physician 2010; 13:E111-E140.
20. Manchikanti L, Damron KS, McManus C, Barnhill R. Patterns of illicit drug use and opioid abuse in patients with chronic pain at initial evaluation: A prospective observational study. Pain Physician 2004; 7:431-437.
21. Manchikanti L, Manchukonda R, Pampati V, Damron KS, Brandon DE, Cash KA, McManus CD. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician 2006; 9:123-129.
22. Manchikanti L, Cash KA, Damron KS, Manchukonda R, Pampati V, McManus CD. Controlled substance abuse and illicit drug use in chronic pain patients: An evaluation of multiple variables. Pain Physician 2006; 9:215-226.
23. Manchikanti L, Manchukonda R, Pampati V, Damron KS. Evaluation of abuse of prescription and illicit drugs in chronic pain patients receiving short acting (hydrocodone) or long acting (methadone) opioids. Pain Physician 2005; 8:257-261.
24. Cone EJ, Caplan YH, Black DL, Moser F. Urine drug testing of chronic pain patients: Licit and illicit drug patterns. J Anal Toxicol 2008; 32:530-543.
25. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan M, Fishbain D, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, O'Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd K, and Miaskowski C. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10:113-130.
26. Pesce A, West C, West R, Crews B, Mikel C, Almazan P, Rosenthal M, Latyshev S, Horn P. Reference intervals: A novel approach to detecting drug abuse in a pain patient population. J Opioid Manag 2010; 6:341-350.
27. Reece AS. Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program. Subst Abuse Treat Prev Policy 2007; 2:35.
28. Beynon CM, Bellis MA, McVeigh J. Trends in drop out, drug free discharge and rates of re-presentation: A retrospective cohort study of drug treatment clients in the North West of England. BMC Public Health 2006; 6:205.
29. Goldsmith R. Addiction and Substance Abuse. In: Pesce A, Kaplan L (eds). Clinical Chemistry: Theory, Analysis, Correlation 5th ed. Mosby/Elsevier, St. Louis, MO, 2010, pp 1110-1115.
30. Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic non-cancer pain: Results of a prospective survey. Pain 2003; 102:211-216.
31. Burns TL, Ineck JR. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann Pharmacother 2006; 40:251-260.
32. Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers 2007; 4:1729-1743.
33. McCarberg BH. Cannabinoids: Their role in pain and palliation. J Pain Palliat Care Pharmacother 2007; 21:19-28.
34. Rosenthal M, Moore P, Groves E, Iwan T, Greenberg-Schlosser L, Dzieqanowska Z, Negro-Vilar A. Sleep improves when patients with chronic OA pain are managed with morning dosing of once a day extended release morphine sulfate (Avinza): Findings from a pilot study. J Opioid Manag 2007; 3:145-154.